A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Clinical trial NCT04300556 · RECRUITING
Trial details
- NCT number
- NCT04300556
- Sponsor
- Eisai Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-06
- Primary completion
- 2030-08-08
- Enrollment
- 182
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.